Lama Ghazi1, Tanja Dudenbostel, Chee Paul Lin, Suzanne Oparil, David A Calhoun. 1. aDepartment of Medicine and Cardiovascular Disease, Vascular Biology and Hypertension Program bCenter for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
OBJECTIVE: Resistant hypertension (RHTN), blood pressure (BP) at least 140/90 mmHg despite using at least three different medications, including a diuretic, is associated with high dietary sodium and hyperaldosteronism. Mineralocorticoid receptor antagonists are recommended for treatment of RHTN, however, BP response to these agents varies widely. In the current analysis, we assessed predictors of BP response to spironolactone in patients with RHTN. METHODS: We retrospectively evaluated the BP response to adding spironolactone 12.5-25 mg to existing medications. A favorable BP response was defined as a reduction in SBP of at least 10 mmHg. Tested variables included baseline characteristics and biochemical parameters. RESULTS: A total of 79 patients with RHTN were included in the analysis. Evaluated patients were more likely women (53.2%) and African-American (55.8%); were generally obese (76%) and were prescribed an average of four antihypertensive medications. Baseline SBP was 153.6 ± 22.3 mmHg; addition of spironolactone resulted in a mean reduction of 15.5 ± 20.7 mmHg. Patients with high urinary sodium excretion (≥200 mEq/24 h) had a significantly greater BP reduction compared with patients with normal excretion (<200 mEq/24 h) (P = 0.008). Multivariable analysis identified 24 h urinary sodium excretion as a significant predictor of BP response (P = 0.021) after controlling for potential confounders, including primary aldosteronism. CONCLUSION: The antihypertensive effect of spironolactone is positively related to urinary sodium excretion regardless of aldosterone status. These findings suggest that mineralocorticoid receptor antagonists may be of preferential benefit in counteracting the BP effects of high dietary sodium.
OBJECTIVE: Resistant hypertension (RHTN), blood pressure (BP) at least 140/90 mmHg despite using at least three different medications, including a diuretic, is associated with high dietary sodium and hyperaldosteronism. Mineralocorticoid receptor antagonists are recommended for treatment of RHTN, however, BP response to these agents varies widely. In the current analysis, we assessed predictors of BP response to spironolactone in patients with RHTN. METHODS: We retrospectively evaluated the BP response to adding spironolactone 12.5-25 mg to existing medications. A favorable BP response was defined as a reduction in SBP of at least 10 mmHg. Tested variables included baseline characteristics and biochemical parameters. RESULTS: A total of 79 patients with RHTN were included in the analysis. Evaluated patients were more likely women (53.2%) and African-American (55.8%); were generally obese (76%) and were prescribed an average of four antihypertensive medications. Baseline SBP was 153.6 ± 22.3 mmHg; addition of spironolactone resulted in a mean reduction of 15.5 ± 20.7 mmHg. Patients with high urinary sodium excretion (≥200 mEq/24 h) had a significantly greater BP reduction compared with patients with normal excretion (<200 mEq/24 h) (P = 0.008). Multivariable analysis identified 24 h urinary sodium excretion as a significant predictor of BP response (P = 0.021) after controlling for potential confounders, including primary aldosteronism. CONCLUSION: The antihypertensive effect of spironolactone is positively related to urinary sodium excretion regardless of aldosterone status. These findings suggest that mineralocorticoid receptor antagonists may be of preferential benefit in counteracting the BP effects of high dietary sodium.
Authors: Mari K Nishizaka; Monique Pratt-Ubunama; Mohammad A Zaman; Stacey Cofield; David A Calhoun Journal: Am J Hypertens Date: 2005-06 Impact factor: 2.689
Authors: Willem De Keyzer; Inge Huybrechts; Arnold L M Dekkers; Anouk Geelen; Sandra Crispim; Paul J M Hulshof; Lene F Andersen; Irena Řehůřková; Jiří Ruprich; Jean-Luc Volatier; Georges Van Maele; Nadia Slimani; Pieter van't Veer; Evelien de Boer; Stefaan De Henauw Journal: Br J Nutr Date: 2011-12-05 Impact factor: 3.718
Authors: Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun Journal: Arch Intern Med Date: 2008-06-09
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: John S Clemmer; Jessica L Faulkner; Alex J Mullen; Kenneth R Butler; Robert L Hester Journal: Biol Sex Differ Date: 2019-05-09 Impact factor: 5.027